Tag Archives: Neulasta

Coherus reveals biosimilar launch tactics in battle against Amgen’s Neulasta

Coherus dialed up pressure on Amgen with a recent FDA approval for a Neulasta biosimilar, and now the company has unveiled its bid for a market share steal, using a discounted price and patient and reimbursement services. Udenyca will carry a list price of $ 4,175, a 33% discount to Amgen’s key drug, executives said… Read More »